← All medicines

Cancer medicines

Iberdomide

Independent educational summary · Sources checked November 20, 2026

Used in an approved combination regimen for selected previously treated multiple myeloma; FDA granted accelerated approval in August 2026.

Profile scope: Iberdomide. Confirm the exact product and route; formulations and combination products are not interchangeable.

Possible side effects

Fatigue, digestive symptoms, body aches, or balance problems may occur.

Serious risks and warning signs

Blood clots can cause stroke, heart attack, or death. Pregnancy exposure can harm a developing fetus; restricted prescribing and pregnancy-prevention requirements apply. Infection symptoms need prompt assessment, and additional cancers are a concern.

A question for your healthcare team

What clot prevention, pregnancy precautions, and infection monitoring are required for my combination regimen?

What to do with this information

Discuss persistent or troubling symptoms with your prescriber or pharmacist. For severe breathing difficulty, collapse, a seizure, or inability to wake someone, seek emergency help. Read the linked medicine information for drug-specific instructions, including situations requiring immediate action. For routine treatment changes, consult your prescriber rather than changing your dose on your own. Follow the urgent action instructions above and in the linked medicine information.

Sources

Sources checked November 20, 2026. An original AI-assisted educational summary, not a complete adverse-effect or interaction list. This profile is part of the broader library expansion, not the original prescription-use ranking. Inclusion does not confirm current product availability or mean that risks outweigh benefits. This page has not been independently reviewed by a clinician.